JPRN-UMIN000026527
Completed
Phase 2
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer(WJOG9216G) - Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer(WJOG9216G, RECAST)
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- first-line treatment in patients with metastatic colorectal cancer
- Sponsor
- West Japan Oncology Group
- Enrollment
- 120
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Serious complications. 2\) Receipt of a blood transfusion or hematopoietic factor therapy within 2 weeks prior to registration. 3\) Grade \>\=2 peripheral sensory neuropathy. 4\) History of Grade \>\=3 thromboembolism within 6 months before the scheduled treatment start date. 5\) Receiving anti\-platelet agents. Aspirin use at doses up to 325 mg/day is permitted. 6\) Women who are pregnant, breastfeeding, had a positive pregnancy test, or women and men who do not wish to use contraception.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer (WJOG9216G)JPRN-jRCTs041180166Kito Yosuke120
Completed
Phase 2
Randomized phase II trial of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with KRAS wild metastatic colorectal cancer refractory to oxaliplatin and bevacizumab with exploratory analysis to predict treatment efficacy and prognosisColorectal cancerJPRN-UMIN000005216West Japan Oncology Group200
Active, not recruiting
Phase 1
Evaluation of the efficacy of a combinaison treatment based upon immunotherapy + chemotherapy to treat patient with a stomach cancerAdvanced gastric or gastro-oesophageal junction adenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10042080 Term: Stomach cancer System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10026476 Term: Malignant neoplasm of stomach System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-002014-13-FRFédération Francophone de Cancérologie Digestive94
Active, not recruiting
Not Applicable
A randomized phase II study of FOLFORI plus or not CETUXIMAB in elderly advanced colorectal cancer patients.Elderly mestatic colorectal cancer patients, Wild-type KRAS ,70-80 years of age, ECOG 0-1.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-000477-23-ITAZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
Active, not recruiting
Phase 1
Comparison of chemotherapy with radiochemotherapy as treatment of patients with locally advanced, primarily inoperable pancreatic carcinomalocally advanced, primarily inoperable pancreatic carcinomaTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-001850-24-ATABCSG (Austrian Breast & Colorectal Cancer Study Group)112